The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
Open accessAbstract
Introduction: The National Institute on Aging—Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum. Methods: The National Institute on Aging—Alzheimer's Association Framework is considered as it applies to clinical trials. Results: Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease‐modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T−N−, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N− and A+T+N+. Discussion: The National Institute on Aging—Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550
Person-specific contribution of neuropathologies to cognitive loss in old age
Boyle, P. A., Yu, L., Wilson, R. S., Leurgans, S. E., Schneider, J. A., & Bennett, D. A. (2018) · Annals of Neurology · doi:10.1002/ana.25123 · Cited by 508
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M. F., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 441
Research works printed but not linked: 2
- U.S. Food and Drug Administration, 2018, Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry, Federal Register, 7060
- Cummings JL, 2017, Defining disease modification for Alzheimer's disease clinical trials, J Prev Alzheimers Dis., 4, 109
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
Self-citationAlzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Moreover, topographical markers for AD include volume modifications in the brain (temporoparietal, hippocampal atrophy, cortical thickness) assessed by magnetic resonance imaging (MRI) and glucose hypometabolism measured by fluorodeoxyglucose (FDG)-PET [73].”
MethodThe degree of frailty as a translational measure of health in aging
Howlett, S. E., Rutenberg, A. D., & Rockwood, K. J. (2021) · Nature Aging · doi:10.1038/s43587-021-00099-3 · Cited by 357
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 351
Self-citation
Metadata
- Authors
- Cummings, J.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Cummings, Jeffrey
- ORCID
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-06-21
- Volume
- 15
- Issue
- 1
- Pages
- 172-178
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC6417790
- OpenAlex
- W2809499549
- Cited by
- 140
- References
- 54
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 25 · 2023: 18 · 2022: 12 · 2021: 21 · 2020: 21 · 2019: 18
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Scholarship - UNLV (University of Nevada Reno) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, United States, Biomarkers, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
